IL33 and early-onset autosomal dominant Alzheimer disease: Because of its role as promoter of type 2 immune responses and regulator of innate and adaptive immune responses, IL-33 has been explored as therapeutic option in pre-clinical models of Alzheimer’s disease [37], stroke [38], cerebral malaria [39], and transplantation [40].